Best Promising Stocks To Watch Right Now

With the SPDR S&P Biotech Index up 38% over the trailing-12-month period, it’s evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let’s have a look at some of the rulings, studies, and companies that made waves in the sector last week.

With the American Society of Clinical Oncology’s annual meeting right around the corner, we were privy to plenty of clinical data (both good and bad), a three-month early drug approval from the Food and Drug Administration, and a head-scratcher of a deal in the biotech sector.

Starting in reverse, Elan (NYSE: ELN  ) surprised investors on Monday by coming out of the bleachers and entering into a $1 billion royalty deal with Theravance (NASDAQ: THRX  ) . If you recall, Theravance and development partner GlaxoSmithKline (NYSE: GSK  ) received FDA approval for their long-acting COPD maintenance inhaled treatment Breo Ellipta last week. The companies are also working on Breo Anoro which is also under FDA review and two additional compounds. The deal by Elan entitles it to receive 21% of Theravance’s royalties and assumes that the remainder of respiratory treatments will be quite successful. While a fantastic deal for Theravance shareholders, it’s a hefty price to pay for Elan, which appears to be wildly reaching for growth ideas.

Best Promising Stocks To Watch Right Now: Verifone Systems Inc.(PAY)

Verifone Systems, Inc. designs, markets, and services electronic payment solutions in North America and internationally. It provides system solutions, including countertop electronic payment systems that accepts magnetic, smart card, contactless/ radio frequency identification(RFID) cards, and near field communication(NFC) enabled mobile phones; secure PIN pads that support credit and debit transactions; and wireless system solutions that support Internet protocol-based code division multiple access, general packet radio service, bluetooth, and wireless fidelity technologies. The company also offers products for consumer-activated functionality at the point of sale; contactless/NFC payment solutions consisting of contactless readers primarily for consumer-activated transactions with contactless cards, tokens, and NFC-enabled mobile phones; and Gemstone family of products comprising integrated electronic payment systems for petroleum companies. In addition, it provides serv er-based payment processing software and middleware; unattended and self-service payments hardware and software integration modules, such as vending machines, ATMs, ticketing kiosks, petroleum dispensers, public transportation turnstiles and buses, self-checkout, bill payment, and photo finishing kiosks; retail bank branch solutions; mass transportation solutions; and network access solutions. Further, the company offers client services, customized application development, advertising publishing, taxi payments and advertising, cardholder data security, annual software maintenance program, and repair services. It serves financial institutions, payment processors, petroleum companies, large retailers, taxi fleets, government organizations, healthcare companies, independent sales organizations, and advertisers. The company was formerly known as VeriFone Holdings, Inc. and changed its name to VeriFone Systems, Inc in May 2010. VeriFone Systems, Inc. is headquartered in San Jose , California.

Advisors’ Opinion:

  • [By Dan Burrows]

    VeriFone (PAY) surged Wednesday on quarterly results showing that although the electronic payments processor is under assault from all sides, the market-share leader still has plenty of life left — as does PAY stock.

  • [By Monica Gerson]

    Breaking news

    Energy XXI (NASDAQ: EXXI) and EPL Oil & Gas (NYSE: EPL) today announced the signing of a definitive merger agreement pursuant to which Energy XXI will acquire all of EPL’s outstanding shares for total consideration of $2.3 billion, including the assumption of debt. To read the full news, click here. Achaogen (NASDAQ: AKAO) announced today the pricing of its initial public offering of 6,000,000 shares of its common stock at a price to the public of $12.00 per share. To read the full news, click here. Geron (NASDAQ: GERN) announced today that the company has received verbal notice from the U.S. Food and Drug Administration (FDA) that its Investigational New Drug (IND) application for imetelstat has been placed on full clinical hold, affecting all ongoing company-sponsored clinical trials. To read the full news, click here. VeriFone (NYSE: PAY) jumped 9.5% in pre-market trading after the company reported its first quarter results. The firm reported a Q1 EPS of $0.31 versus the Street estimate of $0.27. To read the full news, click here.

    Posted-In: Credit Suisse US Stock FuturesNews Eurozone Futures Global Pre-Market Outlook Markets

Best Promising Stocks To Watch Right Now: ITonis Inc (ITNS)

ITonis Inc., incorporated on July 5, 2005, operates as a holding company. The Company focuses to purchase entrepreneurial companies that have established themselves, or are expected to establish themselves in various markets.

The Company invests in small growth entrepreneurial companies. In May 2011, the Company acquired Performance Mortgage Group, Inc., as a wholly owned subsidiary.

Advisors’ Opinion:

  • [By Peter Graham]

    What’s the Catch With MyEcheck Inc? According to various disclosures, transactions of $500 and $2k have or will occur to mention MyEcheck Inc in various investment newsletters. The most recent news for MyEcheck Inc is not so recent as it dates from last April and was an announcement that the company would license its proprietary system to other operators for a share of their transaction revenue on the system with the CEO pointing out: “In addition to our processing revenue, we will have licensing revenue that will exceed our processing revenue in a relatively short period of time.” However, a quick look at MyEcheck Inc’s financials reveals revenues of $3k (most recent reported quarter), zero, zero and zero for the past four quarters along with net income of $387k (most recent reported quarter) and net losses of $8k, $35k and $14k. At the end of last June, MyEcheck Inc had no cash to cover $804k in current liabilities. So maybe investor will want to wait for evidence of licensing and processing revenue to materialize.

    ITonis Inc (OTCMKTS: ITNS) Recently Announced Its First Order

    Small cap ITonis Inc is an Orange County, California based holding company established in 2005 that’s is currently undergoing a company-wide transformation to embark upon an aggressive acquisition plan to purchase high growth entrepreneurial companies that have established themselves, or are expected to establish themselves as leaders in various market niches. On Friday, ITonis Inc fell 9.09% to $0.003 for a market cap of $2.56 million plus ITNS is down 80.3% over the past year and down 50% over the past five years according to Google Finance.

Best Promising Stocks To Watch Right Now: iMD Companies Inc (ICBU)

IMD Companies, Inc., formerly Optimum Mobile Imaging, Corp, incorporated in 1993, is focused on products and services in the health and fitness nutraceutical and medical diagnostics services markets. The Company provides mobile Ultrasound imaging services. It also provides Echocardiography and Vascular Ultrasound services, including Carotid, Arterial with ABI (ankle-brachial index) and Venous duplex ultrasound. The equipment will be transported into customer’s facility on a medical cart by its technologist who will perform all tests in one of customer’s exam rooms. In February 2011, the Company completed the acquisition of Integrated Medical Diagnostics, Inc. In January 2014, the Company announced that it has formed a partnership with Anything Technologies Media Inc. by acquiring 51% interest in R-Quest Hydroponics, Inc., developer of the environmental master controller for medical and recreational marijuana hydroponic gardens. In January 2014, IMD Companies Inc and Anythi ng Technologies Media Inc announced that they jointly acquired Green Linx Inc., and will split revenue on a 50:50 basis.

MyLab30 by Biosound implements phased array technology for cardiac imaging, linear array for vascular and small parts imaging, as well as curved array and microconvex for general imaging. The system allows for the evaluation of the heart, vasculature and organs of the body with the appropriate transducer technology and the appropriate measurement and analysis packages.

Advisors’ Opinion:

  • [By Peter Graham]

    Small cap marijuana stocks IMD Companies Inc (OTCMKTS: ICBU), Tauriga Sciences Inc (OTCMKTS: TAUG), ML Capital Group Inc (OTCBB: MLCG) and Lexaria Corp (OTCMKTS: LXRP) are aiming to give investors a high with their latest news. However, only one of these small cap marijuana stocks appears to be the subject of minor paid promotion or investor relations type of activities. So will investors and traders alike get a high off of these small caps? Here is a quick reality check:

    IMD Companies Inc (OTCMKTS: ICBU) Has a Funding Commitment for Over $1 Million

    Small cap IMD Companies is a Florida corporation, engaged in the medical diagnostics and health and fitness industries. The company is currently positioned to be a holding company for major acquisitions in the medical, and marijuana industry. On Friday, IMD Companies rose 7.82% to $0.120 for a market cap of $19.35 million plus ICBU is up 264.7% over the past year and up 23,900% over the past five years according to Google Finance.

  • [By Peter Graham]

    Small cap stocks Frontier Beverage Company Inc (OTCMKTS: FBEC), IMD Companies Inc (OTCMKTS: ICBU) and Dmh International Incorporated (OTCBB: DMHI) were all mimicking the Titanic last Friday by sinking 41.18%, 32.5% and 28.16%, respectively, last Friday. Moreover, all three of these stocks have been the subject of paid promotions or investor relation campaigns. With the promotions in mind, is it to late to dump these small cap stocks or will this week present a buying opportunity? Here is a closer look:

Best Promising Stocks To Watch Right Now: Nyxio Technologies Corp (NYXO)

Nyxio Technologies Corporation, incorporated on June 08, 2006, through its wholly owned subsidiary Nyxio Technologies Inc. (Nyxio), develop and provide technology for the entertainment and commercial markets within the consumer electronic industry. The Company’s product includes VioSphere Smart television (TV), a flat screen TV with a fully integrated personal computer.

The Realm is an all in one personal computer (PC)/ TV, combining the latest in PC technology with high definition (HD) TV. The Realm Pro, which is all in One PC/TV geared for commercial and digital signage markets. Venture MMV, which is a mobile media viewer is a new class of video eyewear offering designer styling in a sleek ergonomic design with features and performance. The Vuzion is a TV with Android operating system (OS) built in enabling 400,000 Android applications on a TV.

The Company competes with Sony, Samsung, LG, Vizio, Apple, Dell, and HP.

Advisors’ Opinion:

  • [By Peter Graham]

    Nyxio Technologies Corp (OTCMKTS: NYXO), COREwafer Industries Inc (OTCMKTS: WAFR) and NanoTech Entertainment, Inc (OTCMKTS: NTEK) are three small cap stocks in some very diverse industries. In fact, one of these stocks just bought a 3D ice sculpture business. So will investors see their investment melt with that small cap stock along with the other two? Here is a closer look to help you decide for yourself:  

Best Promising Stocks To Watch Right Now: Edp Energias de Portugal SA (EDPFY.PK)

EDP Energias de Portugal SA (EDP), incorporated in 1976, is a Portugal-based company engaged in the electric energy and gas sectors. The Company develops its activities in the business areas of generation, supply and distribution of electricity and supply and distribution of gas. The Company operates through six business units: Electricity Generation, Renewable Energies, Electricity Distribution, Electricity Supply, Gas and Brazil Operations. EDP is also present in electricity generation, supply and distribution in Brazil, Spain and the United States. In April 2008, the Company acquired EDP Renovaveis through Nuevas Energias de Occidente (NEO). In February 2008, Horizon Wind Energy, LLC, EDP’s 100%-owned subsidiary for United States wind operations, acquired from Hydra Energy, LLC, a portfolio of six early stage projects in an aggregate of 1,050 megawatts of wind capacity, located in the States of Illinois, Indiana and Ohio, the United States.

Electricity Generatio n

In Spain, EDP operates through HC Energia. Cogeneration consists of simultaneous production of power and steam using thermal technology, such as in the form of natural gas turbines. Cogenerators are usually attached to an industrial customer or services, to which they supply the electricity and steam they need. Energy generation includes a centralised energy management platform responsible for actively managing the price and volume risks for the EDP Company’s portfolio in the Iberian Peninsula.

Renewable Energies

The Company’s electricity from renewable energies is generated by its subsidiary NEO, and in the United States of America by its subsidiary Horizon Wind Energy. In July 2007, EDP acquired 100% interest in Horizon, a developer, owner and operator of wind power generation in the United States, from the Goldman Sachs Group, Inc. In September 2007, Horizon owned 941 gross megawatt of operating wind projects and has 615 megawa tt of projects under construction, for expected operational ! capacity of 1.556 gross megawatts (1.324 net megawatts).

Electricity Distribution

EDP develops the regulated electricity distribution activity in mainland Portugal and in Spain in the Asturias region and to a lower extent in Madrid, Valencia and Alicante. Electricity distribution activity is a regulated activity that consists in bringing the electricity, through the distribution network, from the transport network substations to the final consumption points. Within the scope of this activity, EDP builds, operates and maintains the distribution network and other installments aimed at electricity distribution, granting service quality and direct and customized assistance.

EDP Distribuicao Energia, S.A. is EDP’s company operating in the regulated distribution and supply businesses in Portugal. EDP’s distribution activity is regulated by energy service regulator (ERSE), which defines the tariffs, parameters and prices for electricity a nd other services in Portugal, controlling and assuring the levels of quality and service demanded by the Direccao Geral de Geologia e Energia (DGGE). EDP Distribuicao is holder of an open-ended binding license for the business of distribution of medium- and high-voltage electricity in mainland Portugal. It is also the concessionaire for almost all the low-voltage distribution network, in accordance with concession contracts with the municipalities. HC Energia operates in the regulated electricity distribution and supply business, with its natural market being the region of Asturias. HC Energia’s network covers the Asturias, Valencia, Madrid and Alicante regions.

Electricity Supply

EDP’s electricity supply offers the services, such as maintenance and assistance services, services aimed at electricity quality, specialized technical services and energy efficiency services. EDP operates in Portugal through EDP Comercial, while in Spain, its electric ity supply service is obtained from HC Energia or Naturgas, ! which off! ers its customers an integrated portfolio of gas and electricity products.


EDP has a presence in the gas sector in the Iberian Peninsula, through Naturgas in Spain, and through EDP Gas in Portugal. Naturgas market is the Basque Country, and Asturias, and it operates in the Spanish gas sector by providing services, such as transport, distribution and supply of gas; supply of gas in the liberalized market, and sourcing and trading.

Brazil Operations

EDP is present in Brazil through Energias do Brasil, a 62.4%-owned subsidiary. Energias do Brasil operates in the electricity generation, distribution and supply businesses.

Advisors’ Opinion:

  • [By David Hunkar]

    Current Dividend Yield: 6.43%
    Sector: Telecom
    Country: Australia

    Company: Edp Energias De Portugal SA (EDPFY.PK)

    Current Dividend Yield: 4.68%
    Sector: Electric Utilities
    Country: Portugal

Best Promising Stocks To Watch Right Now: Marin Software Inc (MRIN)

Marin Software Incorporated, incorporated on March 16, 2006, provides cloud-based digital advertising management platform to advertisers and agencies. The Company’s Revenue Acquisition Management platform is a software-as-a-service (SaaS), analytics, workflow, and optimization solution for marketing professionals, enabling them to manage their digital advertising spend across search, display, social and mobile advertising channels. Its platform integrates with publishers, such as Baidu, Bing, Facebook, Google, Yahoo! and Yahoo! Japan, as well as Web analytics and ad-serving solutions, and key enterprise applications to enable marketers to measure the return on investment of their marketing programs.

The Company’s software platform serves as a system-of-record for advertising performance, revenue and conversion data and allows advertisers to correlate advertising spend to subsequent revenue outcomes or business events. It enables its customers to simultaneo usly run large-scale digital advertising campaigns across multiple publishers and channels, making it easy for marketers to create, publish, modify and optimize campaigns in real time.

Advisors’ Opinion:

  • [By Evan Niu, CFA]

    What: Shares of Marin Software (NYSE: MRIN  ) got clobbered today, down by as much as 21% after the company reported earnings.

    So what: Revenue in the first quarter totaled $17.2 million, which resulted in a non-GAAP net loss of $9.4 million, or $0.39 per share. The freshly public software maker saw gross margin decline to 57%, and its losses grew from a year ago. Investors obviously wanted more.

Best Promising Stocks To Watch Right Now: Macy’s Inc (M)

Macy’s, Inc., together with its subsidiaries, operates stores and Internet Websites in the United States. Its retail stores and Internet Web sites sell a range of merchandise, including apparel and accessories for men, women, and children; cosmetics; home furnishings; and other consumer goods. The company also operates Bloomingdale’s Outlet stores that offer a range of apparel and accessories, including ready-to-wear, shoes, fashion accessories, jewelry, handbags, and intimate apparel products. As of January 28, 2012, it operated approximately 840 stores under the names of Macy’s and Bloomingdale’s; and 7 Bloomingdale’s Outlet stores, as well as and The company was formerly known as Federated Department Stores, Inc. and changed its name to Macy’s, Inc. in June 2007. Macy’s, Inc. was founded in 1820 and is based in Cincinnati, Ohio.

Advisors’ Opinion:

  • [By Rich Duprey]

    The combination of the two retailers will create the fourth largest retailer of menswear, behind department-store chains Macy’s (NYSE: M  ) , Kohl’s (NYSE: KSS  ) , and J.C. Penney (NYSE: JCP  ) with 1,700 stores, 23,000 employees, and pro forma sales of $3.5 billion. Yet Men’s Wearhouse has rightly said it’s not going to rebrand Bank’s stores in recognition of the two companies’ separate customer bases and different corporate cultures.

  • [By James Miller Phd]

    Macy´s (M) is operating about 850 stores under the names Macy’s and Bloomingdale’s. Its P/E ratio indicates that the stock is relatively undervalued. So now let’s take a look at the intrinsic value of this company and try to explain to investors the reasons why it is a good buy or not.

  • [By Damian Illia]

    Guess markets its products through a wide brand portfolio and, through six store concepts, the company operates as much as 512 locations in the US and 1,178 internationally, 858 of which are licensees. Its U.S. wholesale customers are large department stores like Macy’s Inc. (M), and Bloomingdale’s.

Best Promising Stocks To Watch Right Now: Credit Suisse Group AG (CSGN.VX)

Credit Suisse Group AG is a Switzerland-based holding company engaged in private banking, investment banking and asset management areas. It operates through four divisions: Private Banking, which consists of the Wealth Management Clients and Corporate & Institutional Clients business; Investment Banking, provides a range of financial products and services, with a focus on client-driven, flow-based and capital-efficient businesses; Asset Management, offers a range of asset class products, including alternative investments, and multi-asset class solutions, including equities and fixed income products, and Shared Services, which provides centralized corporate services and business support for the Company’s divisions. Advisors’ Opinion:

  • [By Dan Strumpf]

    As big macroeconomic headlines recede, ETFs are falling out of favor. ETF volumes have dipped this year to about 16.5% of total equity volumes, down from 16.7% in 2013, according to analysts at Credit Suisse(CSGN.VX) Trading Strategy. The data suggest that investors are increasingly favoring trades in individual stocks.

Best Promising Stocks To Watch Right Now: Powershares Dynamic Leisure And Entertainment Portfolio (PEJ)

PowerShares Dynamic Leisure and Entertainment Portfolio (the Fund) seeks investment results that correspond generally to the price and yield of an equity index called the Dynamic Leisure and Entertainment Intellidex Index (the Leisure and Entertainment Intellidex). The Leisure and Entertainment Intellidex consists of stocks of 30 United States leisure and entertainment companies. These are companies that are principally engaged in the design, production or distribution of goods or services in the leisure and entertainment industries. These companies may include companies that provide goods or services, including television and radio broadcast or manufacture (including cable television); motion pictures and photography; recordings and musical instruments; publishing, including newspapers and magazines; sporting goods and camping and recreational equipment; toys and games, including video and other electronic games; amusement and theme parks; travel and travel-related servic es; leisure apparel or footwear, and owners and operators of sports arenas and gaming casinos, hotels and motels. Stocks are selected principally on the basis of their capital appreciation potential as identified by the AMEX (the Intellidex Provider) pursuant to its Intellidex methodology.

The Fund will normally invest at least 80% of its total assets in common stocks of leisure companies and entertainment companies. The Fund will normally invest at least 90% of its total assets in common stocks that comprise the Leisure and Entertainment Intellidex. The Leisure and Entertainment Intellidex is adjusted quarterly, and the Fund, using an indexing investment approach, attempts to replicate the performance of the Leisure and Entertainment Intellidex. The Fund generally will invest in all of the stocks comprising the Leisure and Entertainment Intellidex in proportion to their weightings in the Leisure and Entertainment Intellidex. The Fund’s investment advisor is P owerShares Capital Management LLC.

Advisors’ Opinion:

  • [By John Udovich]

    The shares of small cap IMAX Corporation (NYSE: IMAX) have slipped more than 10% this week on growth concerns – meaning it might be a good idea to take a closer look at the stock plus its performance verses other cinema stocks like Carmike Cinemas, Inc (NASDAQ: CKEC), Cinemark Holdings, Inc (NYSE: CNK) and Regal Entertainment Group (NYSE: RGC) along with the PowerShares Dynamic Leisure & Entertainment ETF (NYSEARCA: PEJ).

  • [By Mary Anne & Pamela Aden]

    So, for now, the US stock market is the best overall market. So continue holding the stocks you have, which are mostly doing very well. If you want to buy new positions and increase your stock allocation, the following ETFs are among the strongest ETFs, and we recommend them for purchase: SPDR KBW Bank (KBE)

    Consumer Discretionary SPDR (XLY)

    Merrill Lynch Retail HOLDRS (RTH)

    iShares Dow Jones US Financial Service (IYG)

    PowerShares Dynamic Leisure & Entertainment (PEJ)

    Subscribe to The Aden Forecast here…

  • [By John Udovich]

    Labor Day weekend is coming and if you have travel plans, you might be making a stop at a facility owned by small cap TravelCenters of America LLC (NYSE: TA) which is also worth taking a closer look at from an investment standpoint along with the PowerShares Dynamic Leisure and Entertainment ETF (NYSEARCA: PEJ) and iShares Dow Jones Transportation Average ETF (NYSEARCA: IYT).

Best Promising Stocks To Watch Right Now: Forest Laboratories Inc (FRX)

Forest Laboratories, Inc. (Forest), incorporated on April 11, 1956, develops, manufactures and sells branded forms of ethical drug products, most of which requires a physician’s prescription. The Company also focuses on the development and introduction of new products, including products developed in collaboration with licensing partners. Its products include those developed by the Company and those acquired from other pharmaceutical companies and integrated into its marketing and distribution systems. The Company’s principal products include Lexapro, its selective serotonin reuptake inhibitor (SSRI) for the treatment of major depressive disorder (MDD) in adults and adolescents and generalized anxiety disorder (GAD) in adults; Namenda, its N-methyl-D-Aspartate (NMDA) antagonist for the treatment of moderate and severe Alzheimer’s disease; Bystolic, its beta-blocker for the treatment of hypertension; Savella, its selective serotonin and norepinephrine reuptake inhibitor ( SNRI) for the management of fibromyalgia and its newest marketed product Teflaro, a broad-spectrum hospital-based injectable cephalosporin antibiotic for the treatment of adults with community-acquired bacterial pneumonia. On April 13, 2011, the Company acquired Clinical Data Inc. (Clinical Data), a specialty pharmaceutical company.


In June 2011, the Company ahs submitted a New Drug Application (NDA) to the Food and Drug Administration (FDA) for aclidinium (aclidinium bromide), a long-acting antimuscarinic agent developed as an inhaled therapy for the maintenance treatment of chronic obstructive pulmonary disease (COPD). When given by inhalation, aclidinium leads to bronchodilation by inhibiting airway smooth muscle contraction. Aclidinium is rapidly hydrolyzed in human plasma to two major inactive metabolites. Aclidinium is administered to patients using a multi-dose dry powder inhaler (MDPI). This inhaler was designed with a feedback s ystem which, through a ‘colored control window’ and an a! udible click, helps confirm that the patient has inhaled correctly. It contains multiple doses of aclidinium, includes a visible dose-level indicator, and also incorporates features such as an anti-double dosing mechanism and an end-of-dose lock-out system to prevent use of an empty inhaler.


Linaclotide is being investigated for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) and chronic constipation (CC). Linaclotide is an agonist of the guanylate cyclase type-C receptor found in the intestine and acts by a mechanism. Linaclotide increases fluid secretions leading to increased bowel movement frequency and reduces abdominal pain. Linaclotide is administered orally but acts locally in the intestine with no measurable systemic exposure at therapeutic doses and is intended for once-daily administration.


As a result of its acquisition of Clinical Data, Inc. (Clinical Data) complet ed in April 2011, the Company obtained worldwide rights to develop and market Viibryd (vilazodone HCl) a selective serotonin reuptake inhibitor and a 5-HT1A receptor partial agonist developed by Clinical Data for the treatment of adults with major depressive disorder (MDD). Viibryd became available to patients during the June 2011 quarter and was formally launched in the U.S. in late August 2011.


In February 2011, the Company received approval from the United States Food and Drug Administration (FDA) for the marketing of Daliresp (roflumilast). Daliresp is once-daily, orally administered, selective phosphodiesterase 4 (PDE4) enzyme inhibitor, developed by its partner, Nycomed GmbH (Nycomed), as a treatment to reduce the risk of exacerbations in patients with severe chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis and a history of exacerbations.


Namenda (memantine HCl) is an N -methyl-D-Aspartate (NMDA) receptor agonist for the treatmen! t of mode! rate and severe Alzheimer’s disease. In June 2010, Namenda XR was approved by the FDA for the treatment of moderate to severe dementia of the Alzheimer’s type. Namenda XR is a 28 milligrams once-daily extended-release formulation of Namenda. The Company has obtained the exclusive rights to develop and market memantine in the United States by license agreement with Merz Pharma GmbH & Co. KgaA (Merz) of Germany, the originator of the product.


Bystolic is a beta-1 selective beta-blocker with vasodilating properties. Bystolic decreases heart rate and myocardial contractility and suppresses rennin activity. The Company licensed exclusive United States and Canadian rights to Bystolic from Mylan Inc. (Mylan).


Savella (milnacipran HCl) is the Company’s selective serotonin and norepinephrine inhibitor (SNRI) for the management of fibromyalgia. Fibromyalgia is a chronic condition characterized by widespread pa in and decreased physical function. The Company licensed the United States and Canadian rights to develop and commercialize Savella from Cypress Bioscience, Inc. (Cypress). Its license agreement includes two patents covering the use of Savella for the management of fibromyalgia.


In October 2010, the Company received marketing approval from the FDA for Teflaro (ceftaroline) for the treatment of adults with community-acquired bacterial pneumonia, including cases caused by Streptococcus pneumoniae bacteremia and with acute bacterial skin and skin structure infections, including cases caused by methicillin-resistant Staphylococcus aureus. Teflaro is a spectrum, hospital-based injectable cephalosporin antibiotic with activity against Gram-positive bacteria and common Gram-negative bacteria. Teflaro is a member of the cephalosporin class of antibiotics. The worldwide rights (excluding Japan) to Teflaro are in-licensed on an exclusive basis from Takeda Pharmaceutical Company (Takeda). Teflaro is als! o covered! by two United States patents that relate to the ceftaroline formulation that expire in 2021 and that may provide additional exclusivity.


Avibactam is designed to be co-administered with select antibiotics to enhance their spectrum of activity. The Company received the exclusive rights to administer avibactam with ceftaroline as a combination product in North America. Avibactam is a beta-lactamase inhibitor designed to be co-administered with select antibiotics to enhance their spectrum of activity by overcoming beta-lactamase-related antibacterial resistance.


Lexapro’s is a SSRI for the treatment of MDD in adults and adolescents and GAD in adults. Lexapro’s (escitalopram oxalate) single isomer version of citalopram HBr, for the treatment of MDD in adults and adolescents and GAD in adults.


Cariprazine is an oral D2/D3 partial agonist. Cariprazine is also und ergoing Phase III trials for schizophrenia and acute mania associated with bipolar depression, bipolar depression and as an adjunct treatment for MDD.


Levomilnacipran is a once-daily, selective norepinephrine and serotonin reuptake inhibitor, two neurotransmitters known to play an essential role in regulating mood, and is being developed for the treatment of MDD.

GRT 6005

In December 2010, the Company entered into a license agreement with Grunenthal GmbH for the co-development and commercialization of GRT 6005 and its follow-on compound GRT 6006, small molecule analgesic compounds being developed by Grunenthal for the treatment of moderate to severe chronic pain. GRT 6005 and GRT 6006 are compounds with pharmacological and pharmacokinetic profiles that may enhance their effect in certain pain conditions. GRT 6005 has completed initial proof-of-concept studies in nociceptive and neuropathic pain with further Phase II studies planned prior to initiation of Phase III s! tudies.


In June 2010, the Company entered into a license agreement with TransTech Pharma, Inc. (TransTech) for the development and commercialization of TTP399, a functionally liver selective glucokinase activator (GKA) discovered and developed by TransTech for the treatment of Type II diabetes. Early Phase I testing suggests that pharmacological enhancement of glucokinase activity may lower blood glucose in diabetic patients.


In April 2011, the Company entered into an agreement with Blue Ash Therapeutics, LLC (Blue Ash) pursuant to which it acquired the worldwide rights to azimilide, a class III antiarrhythmic agent developed by Proctor & Gamble Pharmaceuticals. Based on its mechanism of action and results of clinical trials, azimilide was determined to be suited for use in patients with a history of life-threatening ventricular arrhythmias and who have an implantable cardioverter defibrillator. In 2010, the FDA ag reed to one additional Phase III study to support a regulatory submission for azimilide in the U.S.


RGH-618 involves a series of compounds that target metabotropic glutamate receptors and are agonists, which represent potential agents for the treatment of anxiety, depression and other central nervous system (CNS) conditions. In March 2012, the Company initiated a Phase I study in healthy volunteers of RGH-618.

Advisors’ Opinion:

  • [By CNNMoney Staff]

    Actavis (ACT, Fortune 500) shares were up after it said earnings doubled in the fourth quarter. The company announced plans earlier this week to buy Forest Laboratories (FRX) for $25 billion. Forest shares were also higher.

  • [By Lauren Pollock]

    Among the companies with shares expected to actively trade in Tuesday’s session are Forest Laboratories Inc.(FRX), Coca-Cola Co.(KO) and Waste Management Inc.(WM)

  • [By Jake L’Ecuyer]

    Leading and Lagging Sectors
    Tuesday morning, the healthcare sector proved to be a source of strength for the market. Healthcare stocks surged 1% in today’s trading. Leading the sector was strength from Forest Laboratories (NYSE: FRX) and Chindex International (NASDAQ: CHDX) on acquisition news.

  • [By Jake L’Ecuyer]

    Leading the sector was strength from Forest Laboratories (NYSE: FRX) and Chindex International (NASDAQ: CHDX) on acquisition news. In trading on Tuesday, non-cyclical consumer goods & services shares were relative laggards, down on the day by 0.2%.